121 related articles for article (PubMed ID: 10941903)
21. Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22.
DiJoseph JF; Popplewell A; Tickle S; Ladyman H; Lawson A; Kunz A; Khandke K; Armellino DC; Boghaert ER; Hamann P; Zinkewich-Peotti K; Stephens S; Weir N; Damle NK
Cancer Immunol Immunother; 2005 Jan; 54(1):11-24. PubMed ID: 15693135
[TBL] [Abstract][Full Text] [Related]
22. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor.
Smith-Jones PM; Vallabhajosula S; Navarro V; Bastidas D; Goldsmith SJ; Bander NH
J Nucl Med; 2003 Apr; 44(4):610-7. PubMed ID: 12679407
[TBL] [Abstract][Full Text] [Related]
23. The BB1 monoclonal antibody recognizes both cell surface CD74 (MHC class II-associated invariant chain) as well as B7-1 (CD80), resolving the question regarding a third CD28/CTLA-4 counterreceptor.
Freeman GJ; Cardoso AA; Boussiotis VA; Anumanthan A; Groves RW; Kupper TS; Clark EA; Nadler LM
J Immunol; 1998 Sep; 161(6):2708-15. PubMed ID: 9743327
[TBL] [Abstract][Full Text] [Related]
24. Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody.
Juweid M; Sharkey RM; Markowitz A; Behr T; Swayne LC; Dunn R; Hansen HJ; Shevitz J; Leung SO; Rubin AD
Cancer Res; 1995 Dec; 55(23 Suppl):5899s-5907s. PubMed ID: 7493367
[TBL] [Abstract][Full Text] [Related]
25. Highly potent CD22-recombinant ricin A results in complete cure of disseminated malignant B-cell xenografts in SCID mice but fails to cure solid xenografts in nude mice.
Van Horssen PJ; Preijers FW; Van Oosterhout YV; De Witte T
Int J Cancer; 1996 Nov; 68(3):378-83. PubMed ID: 8903481
[TBL] [Abstract][Full Text] [Related]
26. Surface-expressed invariant chain (CD74) is required for internalization of human leucocyte antigen-DR molecules to early endosomal compartments.
Moldenhauer G; Henne C; Karhausen J; Möller P
Immunology; 1999 Mar; 96(3):473-84. PubMed ID: 10233730
[TBL] [Abstract][Full Text] [Related]
27. Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts.
Tuscano JM; O'Donnell RT; Miers LA; Kroger LA; Kukis DL; Lamborn KR; Tedder TF; DeNardo GL
Blood; 2003 May; 101(9):3641-7. PubMed ID: 12511412
[TBL] [Abstract][Full Text] [Related]
28. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies.
DiJoseph JF; Armellino DC; Boghaert ER; Khandke K; Dougher MM; Sridharan L; Kunz A; Hamann PR; Gorovits B; Udata C; Moran JK; Popplewell AG; Stephens S; Frost P; Damle NK
Blood; 2004 Mar; 103(5):1807-14. PubMed ID: 14615373
[TBL] [Abstract][Full Text] [Related]
29. Delivery of saporin to human B-cell lymphoma using bispecific antibody: targeting via CD22 but not CD19, CD37, or immunoglobulin results in efficient killing.
Bonardi MA; French RR; Amlot P; Gromo G; Modena D; Glennie MJ
Cancer Res; 1993 Jul; 53(13):3015-21. PubMed ID: 7686448
[TBL] [Abstract][Full Text] [Related]
30. Experimental therapy of disseminated B-Cell lymphoma xenografts with 213Bi-labeled anti-CD74.
Michel RB; Rosario AV; Brechbiel MW; Jackson TJ; Goldenberg DM; Mattes MJ
Nucl Med Biol; 2003 Oct; 30(7):715-23. PubMed ID: 14499329
[TBL] [Abstract][Full Text] [Related]
31. Cellular association and cytotoxicity of anti-CD74-targeted lipid drug-carriers in B lymphoma cells.
Lundberg BB; Griffiths G; Hansen HJ
J Control Release; 2004 Jan; 94(1):155-61. PubMed ID: 14684279
[TBL] [Abstract][Full Text] [Related]
32. CD74 is expressed by multiple myeloma and is a promising target for therapy.
Burton JD; Ely S; Reddy PK; Stein R; Gold DV; Cardillo TM; Goldenberg DM
Clin Cancer Res; 2004 Oct; 10(19):6606-11. PubMed ID: 15475450
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics, biodistribution, and gamma camera imaging of 111In-KC-4G3 murine monoclonal antibody in athymic nude mice with or without human tumor xenografts.
Longley C; Furmanski P; Dienhart DG; Lear J; Bloedow D; Kasliwal R; Bunn PA
Cancer Res; 1990 Sep; 50(18):5954-61. PubMed ID: 2393864
[TBL] [Abstract][Full Text] [Related]
34. Disseminated or localized growth of a human B-cell tumor (Daudi) in SCID mice.
Ghetie MA; Richardson J; Tucker T; Jones D; Uhr JW; Vitetta ES
Int J Cancer; 1990 Mar; 45(3):481-5. PubMed ID: 2307538
[TBL] [Abstract][Full Text] [Related]
35. CD74: a new candidate target for the immunotherapy of B-cell neoplasms.
Stein R; Mattes MJ; Cardillo TM; Hansen HJ; Chang CH; Burton J; Govindan S; Goldenberg DM
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5556s-5563s. PubMed ID: 17875789
[TBL] [Abstract][Full Text] [Related]
36. Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents.
Newton DL; Hansen HJ; Liu H; Ruby D; Iordanov MS; Magun BE; Goldenberg DM; Rybak SM
Crit Rev Oncol Hematol; 2001; 39(1-2):79-86. PubMed ID: 11418304
[TBL] [Abstract][Full Text] [Related]
37. Expression of invariant chain (CD 74) and major histocompatibility complex (MHC) class II antigens in the human fetus.
Badve S; Deshpande C; Hua Z; Lögdberg L
J Histochem Cytochem; 2002 Apr; 50(4):473-82. PubMed ID: 11897800
[TBL] [Abstract][Full Text] [Related]
38. Specific localization, gamma camera imaging, and intracellular trafficking of radiolabelled chimeric anti-G(D3) ganglioside monoclonal antibody KM871 in SK-MEL-28 melanoma xenografts.
Lee FT; Rigopoulos A; Hall C; Clarke K; Cody SH; Smyth FE; Liu Z; Brechbiel MW; Hanai N; Nice EC; Catimel B; Burgess AW; Welt S; Ritter G; Old LJ; Scott AM
Cancer Res; 2001 Jun; 61(11):4474-82. PubMed ID: 11389078
[TBL] [Abstract][Full Text] [Related]
39. Single tumor cell uptake and dosimetry of technetium-99m Fab' or minute anti-CD22 in low-grade B-cell lymphoma.
Lindén O; Hindorf C; Tennvall J; Segrén S; Wingardh K; Strand SE
Cancer; 2002 Feb; 94(4 Suppl):1270-4. PubMed ID: 11877756
[TBL] [Abstract][Full Text] [Related]
40. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]